Stabilization of glycoprotein liquid formulation using arginine: A study with lactoferrin as a model protein

Hyun Jung Kim, Chang Hoon Shin, Chan Wha Kim

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)


The formulation of new biotherapeutics without human serum albumin (HSA) could decrease the potential risk of blood-transmitted diseases and those caused by infectious viruses and other pathogens. In the present study, arginine was examined as a potential alternative to HAS, and bovine lactoferrin (bLf) was used as a representative model glycoprotein since bLf has potential immunomodulatory and antiviral activity. The optimal formulation for the mixture was determined to be 10mM arginine, 15% (w/v) trehalose, and 0.02% (v/v) Tween 80, using a statistical analysis program, Minitab. Analyses were performed using reverse-phase high-performance liquid chromatography (HPLC) and SDS-PAGE. The blf HSA-free formulations lost only 12-20% of blf compared with 46% for control (without additives) after 28 d of storage. Based on long-term stability studies, the HSA-free formulation developed in this study had a stronger effect on the stability of bLf (1.4-fold) than HSA formulation under various storage conditions over 6 months.

Original languageEnglish
Pages (from-to)61-66
Number of pages6
JournalBioscience, Biotechnology and Biochemistry
Issue number1
Publication statusPublished - 2009


  • Arginine
  • Human serum albumin
  • Lactoferrin
  • Liquid formulation
  • Stabilizing agent

ASJC Scopus subject areas

  • Biotechnology
  • Analytical Chemistry
  • Biochemistry
  • Applied Microbiology and Biotechnology
  • Molecular Biology
  • Organic Chemistry


Dive into the research topics of 'Stabilization of glycoprotein liquid formulation using arginine: A study with lactoferrin as a model protein'. Together they form a unique fingerprint.

Cite this